QTTB
Q32 Bio Inc
NASDAQ: QTTB · HEALTHCARE · BIOTECHNOLOGY
$15.60
-3.70% today
Updated 2026-08-07
Market cap
$434.94M
P/E ratio
5.65
P/S ratio
8.09x
EPS (TTM)
$2.59
Dividend yield
—
52W range
$2 – $24
Volume
1.4M
WallStSmart proprietary scores
50
out of 100
Grade: C
Hold
Investment rating
6.0
Growth
B7.0
Quality
B+10.0
Profitability
A+8.3
Valuation
A5/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →211 stocks currently score above 75
Price targets
Analyst target
$44.50
+185.26%
12-Month target
$7.26
-53.46%
Intrinsic (DCF)
$32.38
Margin of safety
+88.17%
0 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 61.90% — above average
+ ROE 71.78% — strong efficiency
+ 88.17% below intrinsic value
+ Debt/equity 0.29x — low leverage
Risks
- Altman Z 0.00 — distress zone
- Negative free cash flow $-6.34M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $6.65M | $-6.65M | $0.00 | $53.74M | $53.74M |
| Net income | $-42.81M | $-53.74M | $-47.73M | $29.82M | $-7.61M |
| EPS | — | — | — | — | $2.59 |
| Free cash flow | $-13.44M | $-18.68M | $-67.79M | $-33.55M | $-6.34M |
| Profit margin | -643.65% | 808.04% | — | 55.49% | 61.90% |
Peer comparison
Smart narrative
Q32 Bio Inc trades at $15.60. representing a P/E of 5.65x trailing earnings. Our Smart Value Score of 50/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. TTM revenue stands at $53.74M. with profit margins at 61.90%. Our DCF model estimates intrinsic value at $32.38.
Frequently asked questions
What is Q32 Bio Inc's stock price?
Q32 Bio Inc (QTTB) trades at $15.60, on a P/E of 5.7x and a P/S of 8.1x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Q32 Bio Inc overvalued?
Q32 Bio Inc carries a Smart Value Score of 50/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $32.38 versus the $15.60 price, a 88.2% margin of safety on a cash flow basis.
What is the price target of Q32 Bio Inc (QTTB)?
The 12-month analyst consensus target is $44.50, about 185.3% above the current $15.60. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Q32 Bio Inc (QTTB)?
Our DCF model estimates intrinsic value at $32.38, a +88.2% margin of safety versus today's $15.60. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Q32 Bio Inc's revenue?
Q32 Bio Inc's trailing twelve-month revenue is $53.74M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio8.09x
ROE71.78%
Beta-0.27
50D MA$12.63
200D MA$6.35
Shares out0.03B
Float0.00B
Short ratio—
Avg volume1.4M
Performance
1 week+2.87%
1 month+39.16%
3 months+201.16%
YTD+369.88%
1 year—
3 years—
5 years—